Oral Valganciclovir Versus Valacyclovir

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine if the rate of cytomegalovirus reactivation during treatment with alemtuzumab (Campath) is reduced by the use of valganciclovir prophylaxis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: Roche Pharma AG
• Treatments: Acyclovir; Alemtuzumab; Ganciclovir; Valacyclovir; Valganciclovir

Criteria

Inclusion Criteria:

• Patients receiving alemtuzumab

• Age > 15

• Signed informed consent form

Exclusion Criteria:

• Active cytomegalovirus disease or infection. Asymptomatic patients with positive CMV pp65 antigenemia will not be excluded.

• Patients with a creatinine clearance of < 10 ml/min as calculated via the Cockcroft-Gault equation.